A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (AURORA-1)

Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight without T2DM.

Start Date31 Aug 2026

Sponsor / Collaborator

Ascletis Pharmaceuticals Co., Ltd.

NCT07743450

/ RecruitingPhase 3

Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and T2DM.

Start Date28 Aug 2026

Sponsor / Collaborator

Ascletis Pharmaceuticals Co., Ltd.

NCT07321678

/ CompletedPhase 2

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus

Start Date22 Jan 2026

Sponsor / Collaborator

Ascletis Pharmaceuticals Co., Ltd.

100 Clinical Results associated with ASC-30

100 Translational Medicine associated with ASC-30

100 Patents (Medical) associated with ASC-30

News (Medical) associated with ASC-30

29 Oct 2026

·www.prnewswire.com

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

- Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combinations. - ASC36o, a once-weekly oral amylin receptor peptide agonist, is the most advanced drug candidate of Ascletis' once-weekly oral peptide pipeline and its Phase I study has started in the U.S. - ASC36o demonstrated a half-life of approximately 7 days and oral bioavailability of 6% to 8% in non-human primates (NHPs), supporting once-weekly oral administration. - Using ASC36o as a cornerstone, Ascletis has developed two first-in-class once-weekly oral peptide fixed-dose combinations (FDCs), ASC36_37o FDC (amylin/GLP-1/GIP/GCG) and ASC36_35o FDC (amylin/GLP-1/GIP). - Ascletis' once-weekly oral peptide pipeline was developed by its Peptide Oral Transport ENhancement Technology (POTENT) that increased oral bioavailability through both gastric and intestinal absorption and reduced within-subject and between-subject variability. HONG KONG, Oct. 19, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive preclinical data demonstrating the long half-lives and superior bioavailability of its industry-leading once-weekly oral peptide pipeline. The industry's most comprehensive once-weekly oral peptide pipeline The foundation of Ascletis' industry-leading once-weekly oral peptide pipeline (Table 1) for the treatment of obesity and other metabolic diseases is a first-in-class once-weekly oral amylin receptor peptide agonist ASC36o (tablet) which is currently in a Phase I study in the U.S. The topline human pharmacokinetic (PK) data of ASC36o are expected by the end of 2026. At steady state in non-human primates (NHPs), ASC36o tablets reached a half-life of up to 167 hours (approximately 7 days) and oral bioavailability of 6% to 8%. In a head-to-head diet-induced obesity (DIO) rat study comparing ASC36 to eloralintide and petrelintide, ASC36 demonstrated 32% and 91%, respectively, greater body weight reduction. Table 1. Ascletis' once-weekly oral peptide pipeline covers all four validated targets, alone and in combination: Notes: FDC: fixed-dose combination; R: receptor; GLP-1R: glucagon-like peptide 1 receptor; GIPR: gastric inhibitory polypeptide receptor; GCGR: glucagon receptor; FDA: the U.S. Food and Drug Administration; IND: Investigational New Drug. First-in-class once-weekly oral fixed-dose combination (FDC) peptides Ascletis' two FDC oral peptides combine its amylin receptor agonist with incretin agonists in a single once-weekly pill: ASC36_37o FDC (tablet), a once-weekly oral quadruple peptide agonist (amylin receptor + GLP-1R/GIPR/GCGR) ASC36_35o FDC (tablet), a once-weekly oral triple peptide agonist (amylin receptor + GLP-1R/GIPR) In NHPs, combining the peptides extended the half-lives beyond that observed with the single agent. The half-life of ASC36o increased from approximately 7 days as monotherapy to approximately 8.8 days in an FDC of ASC36_35o, and approximately 8.3 days in an FDC of ASC36_37o. ASC36o oral bioavailability also rose, from 6% to 8% alone to ≥10% in both FDCs (Table 2). Furthermore, the Company's pipeline includes a once-weekly oral GLP-1/GIP/GCG triple peptide agonist, ASC37o, and a once-weekly oral GLP-1/GIP dual peptide agonist, ASC35o (Table 1). This pipeline gives Ascletis a unique competitive position to significantly expand the population that can be treated with oral agents. Industry-leading oral bioavailability across our once-weekly oral peptide pipeline All five of Ascletis' once-weekly oral peptides/fixed-dose combinations utilize Ascletis proprietary Peptide Oral Transport Enhancement Technology (POTENT). In both dogs and NHPs, POTENT increases oral bioavailability through absorption in both the stomach and the intestines. POTENT also significantly reduces within-subject and between-subject variability after oral dosing. This technology allowed for oral bioavailability of Ascletis' once-weekly oral peptides of up to > 10% at the steady state, with half-lives up to approximately 8.8 days in NHPs (Table 2). These high rates of oral bioavailability combined with extremely long half-lives allows for commercially viable once-weekly dosing of its oral peptides. Table 2. Half-life and bioavailability of oral peptide pipeline at steady state in NHPs Notes: NHPs: non-human primates; FDC: fixed-dose combination; approx.: approximately. "With the start of our U.S. Phase I study, our once-weekly oral peptide platform has crossed another milestone." said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, "Our two FDC tablets are, to our knowledge, the first once-weekly oral fixed-dose combinations of peptides. Together with ASC37o and ASC35o, they give Ascletis what we believe is the most comprehensive once-weekly oral peptide pipeline in the industry, covering all four validated targets: amylin, GLP-1, GIP and GCG receptors. Our POTENT platform increased absorption in both the stomach and the intestine and reduced variability within and between animal subjects, and our unique combinations improved both even further. We look forward to the topline human PK data of ASC36o (tablet) and the submission of Investigational New Drug applications (INDs) for our four additional once-weekly oral peptide programs by year-end." About POTENT Peptide Oral Transport ENhancement Technology (POTENT) is Ascletis' proprietary oral peptide delivery platform. It is designed to increase oral bioavailability and reduce within-subject and between-subject PK variability, so that peptides can be dosed orally once weekly. In NHPs and dogs, POTENT increased peptide absorption at both gastric and intestinal sites. About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potentially best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a once-daily oral small molecule GLP-1R agonist for chronic weight management and diabetes; ASC30_48FDC, a once-daily oral small molecule dual agonist, a fixed-dose combination of ASC30 (GLP-1R agonist) and ASC48 (GIPR agonist), ASC30_48_39FDC, a once-daily oral small molecule triple agonist, a fixed-dose combination of ASC30 (GLP-1R agonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)), ASC39, an eloralintide-like potent selective amylin receptor agonist (SARA) once-daily oral small molecule, ASC30_39FDC, a once-daily oral small molecule dual agonist, a fixed-dose combination of ASC30 (GLP-1R agonist) and ASC39 (amylin receptor agonist (SARA)), ASC36i, an amylin receptor peptide agonist, designed for once-monthly to once-quarterly subcutaneous administration, ASC36_35i FDC, a triple peptide agonist, a fixed-dose combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), designed for once-monthly to once-quarterly subcutaneous administration, ASC35i, a GLP-1R/GIPR dual peptide agonist, designed for once-monthly to once-quarterly subcutaneous administration, ASC37i, a GLP-1R/GIPR/GCGR triple peptide agonist, designed for once-monthly to once-quarterly subcutaneous administration, ASC36_37i FDC, a quadruple peptide agonist, a fixed-dose combination of ASC36 (amylin receptor agonist) and ASC37 (GLP-1R/GIPR/GCGR agonist), designed for once-monthly to once-quarterly subcutaneous administration, ASC36o, an amylin receptor peptide agonist, designed for once-weekly oral administration, ASC36_37o FDC, a quadruple peptide agonist, a fixed-dose combination of ASC36 (amylin receptor agonist) and ASC37 (GLP-1R/GIPR/GCGR agonist), designed for once-weekly oral administration, ASC36_35o FDC, a triple peptide agonist, a fixed-dose combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), designed for once-weekly oral administration, ASC37o, a GLP-1R/GIPR/GCGR triple peptide agonist, designed for once-weekly oral administration, ASC35o, a GLP-1R/GIPR dual peptide agonist, designed for once-weekly oral administration, for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK). For more information, please visit . Contact: Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) [email protected] Ascletis Pharma Inc. PR and IR Teams +86-181-0650-9129 (China) [email protected] [email protected] SOURCE Ascletis Pharma Inc. 21% more press release views with Request a Demo

Phase 1Clinical ResultPDC

29 Oct 2026

·www.fiercebiotech.com

Ascletis’ challenger to Lilly’s Foundayo hits goals in phase 2 diabetes trial

A phase 2 trial of Ascletis’ oral GLP-1 drug candidate has hit its primary and secondary endpoints, positioning the Chinese biotech to mount a two-front attack on Eli Lilly’s Foundayo. Investigators randomized 100 people with Type 2 diabetes to receive one of three doses of ASC30, Ascletis’ small-molecule GLP-1 receptor agonist, or placebo. HbA1c, a measure of blood sugar, had fallen by 1.6% to 1.7% over 12 weeks across the three ASC30 doses when adjusted for placebo, from a baseline of 8.3%. This hit the study's primary endpoint, according to Ascletis. Lilly’s Foundayo set the benchmark for oral small-molecule GLP-1 drugs. In a 68-subject phase 1b trial, Lilly reported Week 12 placebo-adjusted HbA1c declines of up to 1.4%, from a baseline of 8.1%. Ascletis used the efficacy estimand, which evaluates the treatment effect of all randomized eligible participants while adhering to treatment. Lilly didn’t say whether it used the efficacy or treatment estimand. While the effect on HbA1c looks competitive, weight loss on ASC30 in the diabetes trial compared unfavorably to earlier studies of the drug candidate and to assessments of Foundayo. Placebo-adjusted weight loss at Week 13 ranged from 3.8% to 4.4%. Patients had an average body weight of 93.7 kg at baseline. Weight loss in diabetes trials is typically lower than in obesity studies. At Week 12 of its own phase 1b diabetes study, Lilly reported weight loss of up to 5.8 kg on Foundayo, compared to a 0.5 kg gain on placebo. Average baseline body weight in the placebo and Foundayo cohorts was 90.3 kg and 88.4 kg, respectively, indicating that patients lost up to 7.1% of their weight, adjusted for the control. Overweight and obesity are the lead indications for ASC30. Ascletis started two global phase 3 clinical trials in overweight and obesity in August. The smaller of the two pivotal studies is enrolling patients with Type 2 diabetes, while patients with the comorbidity are excluded from the larger trial. Ascletis reported placebo-adjusted weight loss of 7.7% at Week 13 of a phase 2 obesity trial. The pivotal program could position Ascletis to file for FDA approval in obesity by the end of 2028. The diabetes program is less advanced, although, based on the mid-phase data, the biotech believes it has a best-in-class candidate in the indication. Tolerability is part of Ascletis’ pitch for best-in-class status. No patients discontinued treatment because of gastrointestinal adverse events in the phase 2 diabetes trial. The biotech expects gastrointestinal tolerability to significantly improve in the phase 3 diabetes program, which will use a slower titration schedule. The growing role of China as a source of biopharma innovation is one of the hot topics being discussed at Fierce Biotech's high-impact event in London next month. Find out more information and register by clicking on the banner below:

Phase 2Clinical Result

29 Oct 2026

·www.biospace.com

Ascletis’ Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes

- ASC30 reduced HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% from baseline for 40 mg, 60 mg and 80 mg, respectively, at 12 weeks, the primary endpoint. - ASC30 achieved placebo-adjusted weight reduction of 4.4%, 3.8% and 4.0% from baseline for 40 mg, 60 mg and 80 mg, respectively and no plateau was observed, at 13 weeks, a secondary endpoint. - ASC30 titrated weekly to maintenance doses (40 mg, 60 mg and 80 mg) demonstrated favorable safety and tolerability, with zero study discontinuations due to gastrointestinal adverse events. - No hepatic safety signal was observed. HONG KONG , Oct. 28, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today positive topline results from its U.S. Phase II study ( NCT07321678 ) evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of type 2 diabetes mellitus (T2D). This Phase II study is a 13-week U.S. study evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in 100 participants with diabetes. The primary endpoint is HbA1c reduction from baseline at 12 weeks; one of the secondary endpoints are body weight loss from baseline at 13 weeks. ASC30 (40 mg, 60 mg, 80 mg) met the primary and all secondary endpoints, delivering significant HbA1C reduction and weight loss as well as improvements in multiple cardiovascular risk factors. T2D is the second indication in development for ASC30, in addition to obesity. For the primary endpoint, ASC30 demonstrated statistically significant and clinically meaningful HbA1c reduction in participants with diabetes compared to placebo ( p < 0.0001). Placebo-adjusted HbA1c reductions from baseline were 1.7%, 1.6% and 1.7% (least squares mean) for 40 mg (n=20), 60 mg (n=29) and 80 mg (n=28), respectively, at 12 weeks, using the efficacy estimand [1] . Participants had an average HbA1c of 8.3% at baseline. For the secondary endpoint of body weight reduction, ASC30 demonstrated statistically significant and clinically meaningful body weight reduction compared to placebo ( p = 0.001 to 0.003). Placebo-adjusted body weight reduction from baseline was 4.4%, 3.8% and 4.0% (least squares mean) for 40 mg (n=20), 60 mg (n=29) and 80 mg (n=28), respectively and no plateau was observed, at 13 weeks, using the efficacy estimand. Participants had an average body weight of 93.7 kg at baseline. Although titration (once weekly) was fast in the study, ASC30 continued to demonstrate favorable gastrointestinal (GI) tolerability. ASC30 titrated weekly to maintenance doses (40 mg, 60 mg and 80 mg) demonstrated favorable safety and GI tolerability, with zero study discontinuations due to GI adverse events (AEs). The favorable GI tolerability in diabetic participants was consistent with the finding from studies in obese or overweight participants. It is anticipated that GI tolerability will significantly improve in the Phase III diabetic program when titration is slowed down to once every four weeks. There was only one study discontinuation (1/80, 1.3%, hiccup) due to any AEs. The placebo group had zero study discontinuation due to any AEs. In this ASC30 U.S. Phase II diabetic study, all drug-related AEs were only grade 1 (mild) and grade 2 (moderate) in severity. There were no drug-related serious AEs (SAEs). The overall safety pro ASC30 in diabetic participants was consistent with that observed in another Phase II study ( NCT07002905 ) in participants with obesity or overweight. No hepatic safety signal was observed. There were no elevations of alanine transaminase (ALT), aspartate aminotransferase (AST), or total bilirubin (TBL) during the treatment period. For all other safety signals, ASC30 demonstrated a favorable safety pro diabetic participants. "These data demonstrate that ASC30 has the potential to be a best-in-class oral small molecule GLP-1 for diabetes, in addition to a best-in-class oral small molecule GLP-1 for obesity as demonstrated by the efficacy and tolerability from our U.S. Phase II study in participants with obesity or overweight, " said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, "The combination of significant HbA1c reductions, weight loss and favorable tolerability reinforces our confidence in advancing ASC30 as a once-daily oral treatment option for patients with type 2 diabetes." ASC30 was discovered and developed in-house at Ascletis as an investigational small molecule GLP-1R fully biased agonist. The ASC30 global Phase III program for obesity has two pivotal trials (AURORA-1 NCT07743463 and AURORA-2 NCT07743450 ) in the U.S., Europe, and Canada and is currently enrolling approximately 4,600 participants with obesity or overweight. Topline data from the ASC30 global Phase III clinical program for obesity are expected in the third quarter of 2028, with a U.S. Food and Drug Administration (FDA) New Drug Application (NDA) submission for obesity expected by the end of 2028 and a European Medicines Agency (EMA) Marketing Authorisation Application (MAA) submission for obesity expected in early 2029. ASC30 has the potential to become the second oral small molecule GLP-1 receptor agonist available in the U.S. and Europe, if approved. [1] The efficacy estimand is the primary estimand which evaluates the treatment effect of all randomized eligible participants while adhering to treatment. About the U.S. Phase II Study with ASC30 for the Treatment of Diabetes The Phase II study is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 tablets in participants with type 2 diabetes mellitus (7.0% ≤ HbA1c ≤ 10.5% at baseline). The primary endpoint of the Phase II study is the change from baseline in HbA1c at 12 weeks in the treatment group compared with the placebo group. Secondary endpoints include the change from baseline in body weight at 13 weeks in the treatment group compared with placebo group. The Phase II study enrolled 100 participants with type 2 diabetes mellitus at multiple sites across the U.S. The participants were randomly assigned in a ratio of approximately 2:3:3:2 to 40 mg, 60 mg and 80 mg ASC30 tablets and matching placebo tablets, respectively. ASC30 was titrated weekly from 1 mg to maintenance doses of 40 mg, 60 mg and 80 mg. About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist, and ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30 and ASC39, for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK). For more information, please visit . Contact: Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) Peter.vozzo@icrhealthcare.com Ascletis Pharma Inc. PR and IR Teams +86-181-0650-9129 (China) pr@ascletis.com ir@ascletis.com View original content to download multimedia: SOURCE Ascletis Pharma Inc.

100 Deals associated with ASC-30

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	United States	Ascletis Pharmaceuticals Co., Ltd.	28 Aug 2026
Diabetes Mellitus, Type 2	Phase 3	Czechia	Ascletis Pharmaceuticals Co., Ltd.	28 Aug 2026
Diabetes Mellitus, Type 2	Phase 3	Germany	Ascletis Pharmaceuticals Co., Ltd.	28 Aug 2026
Diabetes Mellitus, Type 2	Phase 3	Greece	Ascletis Pharmaceuticals Co., Ltd.	28 Aug 2026
Diabetes Mellitus, Type 2	Phase 3	Poland	Ascletis Pharmaceuticals Co., Ltd.	28 Aug 2026
Diabetes Mellitus, Type 2	Phase 3	United Kingdom	Ascletis Pharmaceuticals Co., Ltd.	28 Aug 2026
Obesity	Phase 3	United States	Ascletis Pharmaceuticals Co., Ltd.	28 Aug 2026
Obesity	Phase 3	Czechia	Ascletis Pharmaceuticals Co., Ltd.	28 Aug 2026
Obesity	Phase 3	Germany	Ascletis Pharmaceuticals Co., Ltd.	28 Aug 2026
Obesity	Phase 3	Greece	Ascletis Pharmaceuticals Co., Ltd.	28 Aug 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06679959 (Company_Website) Manual	Phase 2	Obesity	65	ASC30 SQ depot formulation A1	yuftwyccst(elbewesezt) = vwhqxvjipa aqarjnxckw (sxwbnmwsil ) Met View more	Positive	10 Mar 2026
				ASC30 SQ depot formulation A2	-
NCT07002905 (Company_Website) Manual	Phase 2	Overweight \| Obesity	125	ASC30 20 mg	cwrmdrxhgm(emzphbgayl) = uvuzrqreyk kidrvmcqct (dlehlupqae ) Met View more	Positive	08 Dec 2025
				ASC30 40 mg	cwrmdrxhgm(emzphbgayl) = hqkczddjjr kidrvmcqct (dlehlupqae ) Met View more
NCT06679959 (Corporate Publications) Manual	Phase 1	Obesity	24	ASC30 100mg	jsoizdfzvi(awvwkneljd) = lqnajpyoiz tighsglydl (jhlyotvppy ) View more	Positive	10 Sep 2025
				安慰剂	jsoizdfzvi(awvwkneljd) = uvgebbqzci tighsglydl (jhlyotvppy ) View more
NCT06680440 (NEWS) Manual	Phase 1	Obesity	-	ASC30 20 mg	bzhrozbimv(bigcqvwnxc) = xhcellydjr ezxvepuydz (bzyqzcrbkl )	Positive	28 Aug 2025
				ASC30 40 mg	bzhrozbimv(bigcqvwnxc) = lwufwcwzjh ezxvepuydz (bzyqzcrbkl )
NCT06680440 (Company_Website) Manual	Phase 1	Obesity	-	ASC30 2 mg, 5 mg, 10 mg, 20 mg (mid starting dose, slow titration)	rmokewtlmg(puktjgclrp) = vvtzlcgvbk wuurallefa (qhykqskosy )	Positive	23 Apr 2025
				ASC30 2 mg, 10 mg, 20 mg, 40 mg (mid starting dose, normal titration)	rmokewtlmg(puktjgclrp) = vlxrhnvtyx wuurallefa (qhykqskosy )
NCT06679959 (NEWS) Manual	Phase 1	Obesity	-	ASC30	xamhcftiew(ueewalaame) = kndzocoktw hxgaenixol (zlokrqzbek ) View more	Positive	31 Mar 2025
NCT06680440 (PRNewswire) Manual	Phase 1	Obesity	30	ASC30 average daily dose 9.25 mg (Cohort 1 had four dose levels (2 mg, 5 mg, 10 mg, and 20 mg))	mawuxrtxts(qyzgozetlk) = msuqxjjitm mkmsaxncyy (hitkawrvte )	Positive	19 Feb 2025
				ASC30 average daily dose 18 mg (Cohort 2 had four dose levels (2 mg, 10 mg, 20 mg, and 40 mg))	mawuxrtxts(qyzgozetlk) = vukdwjtbuz mkmsaxncyy (hitkawrvte )
NCT06680440 (PRNewswire) Manual	Phase 1	Obesity	40	Placebo	nfalrnautd(prsjgojcdk) = nfttsyxlgd utbfodqxlq (rbfjdfwqnt )	Positive	21 Jan 2025
				ASC30 2 mg	nfalrnautd(prsjgojcdk) = bcljgkhgcp utbfodqxlq (rbfjdfwqnt )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis